1. The Dawn of Adrenergic Physiology: A Prelude to Discovery

The history of adrenergic receptors is a compelling narrative that spans centuries, beginning with the first anatomical observations of the adrenal glands and culminating in a profound molecular and clinical understanding. This journey reflects the evolution of scientific thought itself, transitioning from macroscopic physiological observation to the precise manipulation of molecular structures. The foundational debates of the late 19th and early 20th centuries set the stage for all subsequent discoveries, laying the intellectual groundwork for what would become a cornerstone of modern pharmacology.

1.1 The Anatomical Groundwork and Isolation of a Pressor Substance

The story of adrenergic physiology begins with the anatomical recognition of the adrenal gland. The Italian anatomist Bartolomeo Eustachio first described the gland in 1564, an observation notably missed by his contemporary Andreas Vesalius in his seminal work, De Corporis Humani Fabrica.¹ Eustachio, surmising its function as an accessory kidney, termed it glandulae renibusincumbentes.¹ For nearly 300 years, the physiological role of this small organ remained a mystery. Its function only began to unravel in 1855, with Thomas Addison’s report on the clinical effects of adrenal insufficiency, now known as Addison’s disease.¹

A pivotal moment arrived in 1894 when British physiologists George Oliver and Edward Schäfer discovered that adrenal gland extracts possessed a potent blood pressure-raising property.¹ This observation, which demonstrated a clear link between the adrenal gland and cardiovascular function, ignited a global race among scientists to isolate the active principle responsible for this “pressor” effect.¹

The quest for this active compound was fraught with challenges. John Abel, an American chemist, made an early attempt in 1899, isolating an inactive, benzoylated derivative he named “epinephrine”.¹ However, it was not until August 1900 that the Japanese industrial chemist Jokichi Takamine, working with his associate Jōkichi Uenaka in New York, succeeded in crystallizing the pure, active principle from adrenal extracts.¹ Takamine named his discovery “adrenalin,” a name that would be trademarked by Parke, Davis & Company for global marketing.¹ This dual nomenclature—”adrenaline” in British and European pharmacology and “epinephrine” in American terminology—is a historical artifact of this early scientific rivalry, where a pursuit of fundamental knowledge was already intertwined with the race for intellectual property and commercial application. This period established an enduring precedent for how commercial interests would shape the formal terminology and dissemination of future pharmacological discoveries.

1.2 The First Great Debate: Chemical Transmission vs. Direct Neural Action

By the late 19th century, it was well-established that sympathetic nerve stimulation produced different effects on various body tissues, but the mechanism of this stimulation was a subject of intense debate.⁴ The prevailing theory was that nerve impulses acted directly on effector organs via a direct electrical or mechanical transmission of the stimulation wave.⁵

A revolutionary, though initially unproven, idea was proposed in 1904 by a young physiologist named T.R. Elliott, working in John Langley’s laboratory.³ Elliott suggested that the active principle, adrenaline, was not a product of nerve stimulation but was, in fact, the chemical substance released from sympathetic nerve terminals to act on smooth muscle cells.³ This hypothesis of “chemical neurotransmission” represented a fundamental departure from the prevailing direct transmission theory.

The debate over the nature of the sympathetic transmitter intensified with the work of Walter Cannon and Arturo Rosenblueth. Interpreting their experiments, they proposed that two distinct substances were released from sympathetic nerve terminals to explain the duality of adrenergic effects: “sympathin E” for excitation and “sympathin I” for inhibition.⁴ Their “two neurotransmitter” hypothesis was a logical attempt to reconcile the observed physiological duality with a dual-messenger system, an intuitive explanation that held sway for some time.⁷

The definitive proof for chemical transmission arrived in 1921 with Otto Loewi’s elegant and now-classical experiments on frog hearts.⁵ By stimulating the vagus nerve to a frog heart and transferring the perfusate to a second, unstimulated heart, he demonstrated that a chemical substance—later identified as acetylcholine—was released to mediate the effect.⁵ Loewi later confirmed a similar mechanism for sympathetic nerves, initially identifying the released substance as adrenaline.⁵ The final piece of the puzzle was provided in 1946 when Ulf von Euler, a Swedish physiologist, conclusively showed that the primary sympathetic transmitter was not adrenaline, but its demethylated derivative, noradrenaline.³

The early and often contentious debates regarding the existence of chemical neurotransmitters and the identity of those transmitters highlight a crucial conceptual struggle in the history of pharmacology. Before Ahlquist’s work, the field was trying to explain the diverse physiological responses to a single chemical agent (adrenaline) by postulating either a dual-transmitter system (Cannon’s sympathins) or an undefined, tissue-specific response mechanism. This foundational confusion and the resistance to a truly “conceptual” framework set the stage for a new way of thinking, demonstrating that even when the chemical mediator was identified, the underlying mechanism of its action remained a profound mystery.

2. The Conceptual Revolution: Raymond Ahlquist’s Paradigm Shift

The resolution of the “sympathin” controversy and the identification of noradrenaline as the primary sympathetic neurotransmitter still left a fundamental question unanswered: how could a single chemical agent produce both excitatory and inhibitory responses in different tissues? The paradigm that a single substance acts on a single type of receptor to produce a single effect was insufficient to explain the complex reality of adrenergic signaling. It was Raymond Ahlquist, an American pharmacist and pharmacologist, who provided the unifying conceptual framework that would revolutionize the field.

2.1 A New Methodology: The Shift from Physiological Effect to Pharmacological Potency

Before Ahlquist’s seminal work, adrenergic effects were often categorized simplistically based on their physiological outcome—as either “excitatory” or “inhibitory”.⁴ This classification system was fraught with contradictions; for instance, adrenaline could both cause blood vessel contraction (an excitatory effect) and intestinal muscle relaxation (an inhibitory effect).⁴ Ahlquist’s brilliance was to move beyond this problematic physiological classification and focus on the pharmacological properties of the drugs themselves.

In his groundbreaking 1948 paper, “A study of the adrenotropic receptors,” Ahlquist investigated the effects of six closely related catecholamine agonists on various organs in multiple species, including dogs, cats, rats, and rabbits.⁷ His key finding was that while the physiological outcome varied by tissue, the relative potency of the six agonists fell into one of two consistent rank orders, regardless of whether the effect was excitatory or inhibitory.⁷

For example, he found that the rank order of potency for inducing vasoconstriction in blood vessels was adrenaline > noradrenaline > α-methyl noradrenaline > isoprenaline.¹⁰ In contrast, the potency for promoting myocardial contraction in the heart followed a different pattern: isoprenaline > adrenaline > α-methyl noradrenaline > norepinephrine.¹⁰ This methodical approach provided an elegant and irrefutable dataset that the prevailing “sympathin” and “excitatory/inhibitory” theories could not explain. The discovery was a byproduct of a research effort to find a drug to relax the myometrium, demonstrating that foundational discoveries often arise from a shift in perspective rather than a direct assault on a central problem.⁸ By changing the classification metric from a variable physiological outcome to a consistent pharmacological characteristic, Ahlquist found an underlying truth that the previous frameworks had obscured.

2.2 The Birth of Alpha and Beta Receptors

Based on the two distinct rank orders of potency he observed, Ahlquist insightfully concluded that the adrenotropic effects were mediated by two different, hypothetical structures.⁷ He tentatively named the receptors with the first rank order (e.g., blood vessel contraction) the “alpha adrenotropic receptor” (alpha-AR), and those with the second rank order (e.g., myocardial stimulation) the “beta adrenotropic receptor” (beta-AR).⁷

Ahlquist’s critical new concept was to define receptor types and subtypes by their pharmacological properties—specifically, their rank order of drug potencies—rather than by the physiological nature of their response.⁷ This new framework provided a unified, logical explanation for the paradoxical effects of a single neurotransmitter like noradrenaline, which could cause both excitation (vasoconstriction via alpha-ARs) and inhibition (smooth muscle relaxation via beta-ARs) depending on which receptor type predominated in a given tissue.⁷ His classification was further supported by the observation that responses mediated by alpha-receptors could be blocked by ergot alkaloids, a class of drugs that had no effect on beta-mediated responses.⁷

2.3 The Struggle for Acceptance: From Abstract Concept to Scientific Pillar

Despite its intellectual elegance and explanatory power, Ahlquist’s theory was not immediately accepted. The manuscript was first rejected by the Journal of Pharmacology and Experimental Therapeutics before finding a home in the American Journal of Physiology.¹⁰ The reluctance to embrace his theory stemmed from a fundamental conceptual barrier. As Sir James Black later explained, the term “receptor” at the time was often viewed as a mere “abstract concept” or a “pure invention” used by pharmacologists to “do the math,” rather than a tangible biological entity.⁷ The idea of a physical structure that could be classified and targeted was so novel that it “stuck in everybody’s throat”.⁷ Even Ahlquist himself was cautious, viewing the receptor as a “useful concept” with “only interim value until the exact nature of the responsive mechanism for adrenergic agonists is discovered”.⁷

The history of this initial resistance provides a powerful lesson in the sociology of science. Scientific progress is not a purely rational process; it is a human endeavor shaped by prevailing beliefs and institutional inertia. While Ahlquist’s data were sound, the scientific community was not yet ready to accept a hypothesis that relied on a concept that was still considered speculative. It would take a subsequent, concrete, and clinically significant discovery—Sir James Black’s development of beta-blockers—to truly validate Ahlquist’s abstract concept and establish it as an undeniable scientific pillar.⁷

3. Refinement and Subtype Elucidation: The Age of Pharmacological Specificity

Ahlquist’s alpha/beta classification provided the essential roadmap for the next several decades of pharmacological research. With a new framework in place, scientists were able to embark on a more detailed exploration of adrenergic signaling, leading to the discovery of multiple receptor subtypes and the development of a new era of highly selective, and clinically transformative, drugs.

3.1 The First Subdivisions: From Alpha/Beta to α1​, α2​, and β1​, β2​

Ahlquist’s two-receptor model was a monumental first step, but it was quickly expanded upon as new pharmacological agents with differing specificities were developed. The discovery of various pharmacological profiles within the alpha and beta classes led to a further sub-classification of adrenergic receptors.

The alpha-adrenoceptors were subdivided into α1​ and α2​ subtypes in 1974.¹⁴ This classification was based on differences in potency for the alpha-adrenoceptor antagonist phenoxybenzamine and was supported by the discovery of presynaptic, release-modulating autoreceptors on nerve terminals, which proved to be a distinct subtype.³

Similarly, the beta-adrenoceptors were divided into β1​ and β2​ subtypes in 1967 by Alonzo M. Lands and his collaborators.² This classification was supported by the subsequent discovery of selective antagonists for each subtype. It was determined that β1​-ARs were predominantly located in the heart and mediated excitatory effects, such as increased heart rate and contractility, while β2​-ARs were found in vascular and airway smooth muscle and were responsible for relaxation, or vasodilation and bronchodilation.²

3.2 The Prolific β-Blockers: James Black’s Pursuit of a Clinical Target

The direct consequence and powerful validation of Ahlquist’s intellectual framework came from the work of Sir James Black. Inspired by Ahlquist’s theory, Black embarked on a deliberate mission to find a drug that could selectively block the “excitatory” β-receptor effect on the myocardium to treat angina pectoris, a condition caused by a lack of oxygen to the heart muscle.¹⁶ This was a remarkable act of translational science—applying an abstract pharmacological theory to a specific clinical problem.

In 1958, Black and his team developed the first clinically effective β-blocker, propranolol, which proved to be a landmark event in the history of cardiovascular therapeutics.¹³ Propranolol’s ability to reduce heart rate and myocardial oxygen demand revolutionized the management of angina and other cardiovascular diseases.¹⁶ This invention, considered one of the most important achievements in 20th-century medicine, earned Black the Nobel Prize in Physiology or Medicine in 1988, a prize that also acknowledged and vindicated Ahlquist’s foundational work.¹⁶

The development of β-blockers has since progressed through three generations, from nonselective agents to cardioselective β1​-antagonists and, finally, to a third generation with additional vasodilating properties, and they remain the mainstay for treating a wide array of cardiovascular conditions, including hypertension, angina, myocardial infarction, and heart failure.²

3.3 Unveiling the Final Subtypes: Molecular and Pharmacological Elucidation

The journey of adrenergic receptor classification continued as new pharmacological and molecular tools became available. In the mid-1980s, the α1​-adrenoceptors were further sub-classified based on their differential affinities for various antagonists like WB4101 and agonists such as oxymetazoline.² These pharmacological studies led to the identification of three native subtypes: α1A​, α1B​, and α1D​.² (The initially named α1C​ subtype was later found to be identical to α1A​, and the D-subtype naming was used to avoid confusion ²).

In 1989, the beta family expanded with the discovery of the β3​-adrenoceptor.²⁰ This receptor, initially noted for its role in thermogenesis and lipolysis in adipose tissue, has since gained attention as a potential target for treating conditions like obesity and even certain cancers, where its upregulation has been observed in the tumor microenvironment.¹⁸

3.4 The Impact on Clinical Practice: The Rise of Selective Drugs

The precise classification of adrenergic receptor subtypes enabled a new era of rational drug design, moving beyond the broad-acting physiological agents like adrenaline and noradrenaline.² The history of adrenergic drugs perfectly illustrates the defining trend of modern pharmacology: the move toward specificity. Early use of adrenaline for asthma was effective but came with significant cardiovascular side effects.² The later use of selective β2​-agonists caused bronchodilation with far fewer side effects, showcasing the value of subtype specificity.⁴

Today, the pharmacopeia of adrenergic drugs is highly refined. For example, selective α1​-antagonists such as tamsulosin are used to treat benign prostatic hyperplasia (BPH) by relaxing prostatic smooth muscle, thereby reducing urinary symptoms with fewer side effects than less selective agents.² Similarly, selective agonists like phenylephrine and oxymetazoline are commonly used for nasal congestion.²

The story of β-blockers in heart failure provides a profound illustration of how deeper receptor understanding can refine clinical practice. Initially, β-blockers were considered a strict contraindication for heart failure patients due to their ability to reduce cardiac contractility.¹³ However, landmark clinical trials at the turn of the century demonstrated a paradoxical but significant benefit of a select group of

β-blockers, leading to a dramatic shift in their use from a contraindication to a mainstay of treatment.¹³ This evolution reflects a nuanced understanding of receptor pathophysiology, where prolonged overstimulation of adrenergic receptors contributes to cardiac remodeling and heart failure progression, and selective inhibition can provide a long-term benefit.¹³ This continuous refinement of clinical knowledge, even for decades-old drugs, is a direct result of the ongoing search for a more nuanced understanding of receptor function and regulation.

4. The Molecular Revolution: From “Concept” to “Entity”

For decades, adrenergic receptors remained a “concept” in the minds of pharmacologists—a useful idea to explain drug action but without a confirmed physical existence. The journey from this abstract concept to a tangible, molecular entity represents one of the most significant revolutions in 20th-century science and medicine.

4.1 The Pioneering Work of Robert Lefkowitz: Radioligand Binding and Receptor Purification

The notion of cellular receptors as physical entities was highly controversial and met with considerable skepticism well into the 1970s.²² Even the great minds of the era, including Sutherland and Ahlquist, viewed them as an “abstract concept”.⁷ Robert Lefkowitz, a young cardiologist who had started his research in 1968, took on the audacious challenge of physically identifying and isolating these receptors.²³

Lefkowitz’s groundbreaking approach involved the development of radioligand binding techniques.²² By attaching a radioactive iodine isotope to various hormones and drugs, he was able to directly trace and quantify the interaction between a ligand and its putative receptor in cell membranes.²⁴ This methodology provided the first direct evidence of a measurable, physical binding site. Using these techniques, his team successfully “tagged” the β-adrenergic receptor and embarked on the daunting task of purifying it.²² The receptors were found to be trace contaminants of plasma membranes, requiring a 100,000-fold purification.²² The key to this success was the development of novel affinity chromatography matrices, which allowed for the selective isolation of the receptor based on its ability to bind specific ligands.²² The isolated molecule was a glycoprotein of approximately 65 kDa that bound specific adrenergic ligands with the same specificity and stereospecificity observed in classical pharmacological experiments, conclusively proving its identity as a receptor.²²

4.2 The Cloning Breakthrough: Brian Kobilka and the β2​-Adrenergic Receptor

Once Lefkowitz’s laboratory had purified the receptor protein, the next great challenge was to understand its fundamental molecular structure. This mission was accepted in the 1980s by Brian Kobilka, a young doctor fascinated by the power of epinephrine in clinical practice.²⁵ Kobilka took on the challenge of isolating the gene that codes for the β2​-adrenergic receptor from the vast human genome.²⁴

Using short amino acid sequences obtained from the purified receptor protein, Kobilka’s team designed oligonucleotide probes to find and clone the corresponding cDNA and gene.²² The successful cloning of the β2​-AR gene was a transformative moment in molecular biology.²² Analysis of the gene’s sequence revealed that the receptor was composed of a single polypeptide chain with seven hydrophobic, transmembrane helical domains.¹⁵

The most profound discovery of this work was a serendipitous one: this seven-helix structure was strikingly similar to that of rhodopsin, the light-capturing receptor in the eye, which was also known to be coupled to a G-protein.¹⁵ This stunning observation demonstrated that adrenergic receptors were not unique but were, in fact, part of a vast and ancient superfamily of proteins known as “G protein-coupled receptors” (GPCRs).¹⁸ This realization provided a unifying framework for understanding how the body senses and responds to an astonishing array of signals—from light and taste to hormones and neurotransmitters.²⁴ The convergence of two seemingly disparate fields—neuropharmacology and vision science—on a shared fundamental biological mechanism was a pivotal moment in the history of biology.

4.3 The Age of Structural Biology: Crystallography and High-Resolution “Snapshots”

The cloning of the β2​-AR provided the molecular blueprint, but the next frontier was to visualize its three-dimensional structure and how it changed upon activation. The β2​-AR, due to its pioneering status, became the “prototypical” GPCR for developing new biophysical methods.²⁹

Kobilka’s laboratory developed innovative techniques, including the generation of T4 lysozyme fusion proteins, to stabilize and crystallize the notoriously difficult-to-study membrane-bound receptors.²⁹ This work yielded the first high-resolution crystal structures of a human GPCR, providing an unprecedented view of its inactive and active states.²⁹ In a monumental achievement, Kobilka’s team captured the first image of the β2​-AR at the exact moment it was activated by a hormone and coupled to its G-protein, providing the first “molecular masterpiece” of transmembrane signaling.²⁴ This work confirmed the long-held theoretical models of GPCR activation, which involved conformational changes in transmembrane helices to open a binding site for the G-protein.²⁸

4.4 The Nobel Legacy: Acknowledging a Half-Century of Groundbreaking Research

The work of Robert Lefkowitz and Brian Kobilka represents a half-century-long pursuit that transformed an abstract “concept” into a physical, understandable “entity”.²³ In 2012, they were jointly awarded the Nobel Prize in Chemistry for their groundbreaking discoveries on the workings of G protein-coupled receptors.²⁴ This award was not for a single discovery but for a decades-long pursuit that provided the tools, validation, and fundamental understanding for an entire field of research. Their work is of profound clinical significance, as approximately half of all modern medications, including

β-blockers, antihistamines, and psychiatric drugs, exert their effects by targeting GPCRs.²⁴ The history of adrenergic receptors is, in many ways, the history of the entire GPCR field, and the methodological breakthroughs pioneered for this single receptor created a positive feedback loop that enabled the discovery and characterization of hundreds of others.

5. Modern Insights and the Ongoing Clinical Legacy

The historical journey of adrenergic receptors, from early anatomical observation to high-resolution structural snapshots, has led to a profound understanding of their role in human health and disease. This knowledge has not only enabled the development of a vast pharmacopeia but continues to inform new areas of research and clinical practice.

The following table provides a comprehensive overview of the nine major adrenergic receptor subtypes, summarizing their primary locations, physiological effects, and key clinical significance.

5.1 A Superfamily of Receptors: From Local Action to Systemic Control

The realization that adrenergic receptors are part of the vast GPCR superfamily provides a unifying understanding for their ubiquitous presence and diverse physiological roles.¹⁸ These receptors are found in nearly every peripheral tissue and on many neuronal populations, serving as the primary mediators of the sympathetic nervous system’s “fight or flight” response.² The diversity of the nine known subtypes is a testament to the evolutionary tinkering that Francis Jacob described, allowing the body to use a common core structure to fine-tune its response to different signals.²⁸ The coupling of different subtypes to distinct G proteins— Gq​ for alpha1​, Gi​ for alpha2​, and primarily Gs​ for beta—explains their varied intracellular signaling pathways and functional outcomes, from smooth muscle contraction and bronchodilation to the regulation of heart rate and metabolism.²

5.2 The Evolving Pharmacopeia: A Legacy of Targeted Therapeutics

The historical and molecular understanding of adrenergic receptors has led to a robust and continuously evolving pharmacopeia.² Early, non-selective agents like adrenaline and noradrenaline are still used today for acute emergencies such as circulatory shock and anaphylaxis.² However, the defining trend of modern medicine is the move toward highly selective agonists and antagonists. Selective α1​-agonists like phenylephrine and oxymetazoline are now common in over-the-counter remedies for nasal congestion, while selective α1​-antagonists (e.g., doxazosin, tamsulosin) are used to manage hypertension and BPH.² The wide-ranging applications of β-blockers in cardiology represent the most significant clinical success of this approach.¹³ The development of selective β2​-agonists for asthma and chronic obstructive pulmonary disease (COPD) has provided effective bronchodilation with fewer off-target effects, a clear clinical benefit of subtype specificity.¹⁸

The history of adrenergic drugs illustrates the profound power of specificity in clinical practice. This refinement from general to specific is the engine of modern drug development. Furthermore, emerging applications, such as the use of β-blockers in cancer research and α2​-agonists for their analgesic effects, demonstrate that this field is still expanding, with new therapeutic targets being identified as our understanding of receptor function continues to deepen.²⁰

5.3 A Look Ahead: Beyond the Classical Model

Despite the monumental progress, the history of adrenergic receptors is an ongoing narrative. Modern research continues to uncover complexities beyond the classical models. The discovery of adrenergic autoreceptors on nerve terminals and the phenomenon of “cotransmission”—where a single neuron can release multiple chemical messengers—demonstrates that the simplicity of a single transmitter acting on a single receptor is an incomplete picture.³

Ongoing research explores the physiological role of lesser-understood subtypes, such as the putative β4​-AR, and the intricacies of receptor regulation, including processes like desensitization, up-regulation, and allosteric modulation.²¹ New drug discovery strategies, such as fragment-based drug design, are now being applied to adrenergic receptors, leveraging high-resolution structural data to design novel ligands that can precisely modulate receptor function.²⁹ The debates surrounding the use of β-blockers in heart failure and COPD, for example, show that even “settled” science is subject to continuous re-evaluation based on a deeper understanding of receptor regulation and pathophysiology.¹³

6. Conclusion: A Synthesis of Science and Medicine

The history of adrenergic receptors is not a linear timeline of isolated discoveries but a single, profound narrative of scientific progression. It is a story that begins with early anatomists and physiologists grappling with the observable effects of an unknown substance, progresses to a conceptual revolution that provided the intellectual framework for pharmacology, and culminates in a molecular revolution that transforms an abstract idea into a tangible, high-resolution reality.

The arc of this history demonstrates the critical role of scientific synergy, where the theoretical frameworks of pharmacology and the technical breakthroughs of biochemistry and molecular biology converged to produce a definitive understanding of a major signaling pathway. From the initial disputes over “sympathins” to the social and conceptual resistance to the “receptor” idea, the journey underscores that scientific progress is a dynamic, often contentious process. The ultimate vindication of Ahlquist’s and Lefkowitz’s theories came not just from compelling data but from the development of a class of life-saving drugs that made their abstract concepts undeniable. The enduring legacy of this research is a testament to the power of fundamental discovery to drive clinical innovation. The continuous refinement of adrenergic receptor-targeted therapies and the ongoing exploration of new subtypes and signaling complexities confirm that the history of this remarkable receptor family is still being written, with each new chapter building upon a foundational story of curiosity, conflict, and collaboration.

Works cited

1. Adrenaline/Epinephrine Hunters: Past, Present, and Future at 1900 – Gavin Publishers,  , https://www.gavinpublishers.com/article/view/adrenaline-epinephrine-hunters-past-present-and-future-at-1900
2. Adrenoceptors | Introduction | BPS/IUPHAR Guide to …,  , https://www.guidetopharmacology.org/GRAC/FamilyIntroductionForward?familyId=4
3. One hundred years of adrenaline: the discovery of autoreceptors,  , https://pubmed.ncbi.nlm.nih.gov/10454061/
4. Adrenergic receptor – Wikipedia,  , https://en.wikipedia.org/wiki/Adrenergic_receptor
5. Otto Loewi – Nobel Lecture – NobelPrize.org,  , https://www.nobelprize.org/prizes/medicine/1936/loewi/lecture/
6. U. S. von Euler – Nobel Lecture,  , https://www.nobelprize.org/uploads/2018/06/euler-lecture.pdf
7. Alpha- and beta-adrenergic receptors: Ahlquist’s landmark …,  , https://journals.physiology.org/doi/10.1152/ajpendo.00664.2007
8. (PDF) Alpha- and beta-adrenergic receptors: Ahlquist’s landmark …,  , https://www.researchgate.net/publication/5888843_Alpha-_and_beta-adrenergic_receptors_Ahlquist’s_landmark_hypothesis_of_a_single_mediator_with_two_receptors
9. Adrenergic agonist – Wikipedia,  , https://en.wikipedia.org/wiki/Adrenergic_agonist
10. Raymond P. Ahlquist – Wikipedia,  , https://en.wikipedia.org/wiki/Raymond_P._Ahlquist
11. A Brief History of Great Discoveries in Pharmacology: In Celebration of the Centennial Anniversary of the Founding of the Americ – ASPET,  , https://www.aspet.org/docs/default-source/uploadedfiles/Knowledge_Center/289-full
12. Ahlquist and the development of beta-adrenoceptor antagonists – PubMed,  , https://pubmed.ncbi.nlm.nih.gov/9627/
13. Beta-Blockers: A Tale of Triumphs, Trials, and Tribulations – PMC,  , https://pmc.ncbi.nlm.nih.gov/articles/PMC6967340/
14. History and nomenclature of alpha1-adrenoceptors – PubMed,  , https://pubmed.ncbi.nlm.nih.gov/10438241/
15. Adrenergic receptors: structure and function – Cleveland Clinic Journal of Medicine,  , https://www.ccjm.org/content/ccjom/57/5/481.full.pdf
16. Beta-blockers: Historical Perspective and Mechanisms of Action,  , https://www.revespcardiol.org/en-beta-blockers-historical-perspective-and-articulo-S1885585719301100
17. Direct Binding Studies of Adrenergic Receptors: Biochemical, Physiologic, and Clinical Implications | Annals of Internal Medicine – ACP Journals,  , https://www.acpjournals.org/doi/10.7326/0003-4819-91-3-450
18. Adrenergic Receptors In Disease and Drug Discovery – Indigo Biosciences,  , https://indigobiosciences.com/adrenergic-receptors-in-disease-and-drug-discovery/
19. Discovery and development of beta-blockers – Wikipedia,  , https://en.wikipedia.org/wiki/Discovery_and_development_of_beta-blockers
20. Inside the Biology of the β3-Adrenoceptor – MDPI,  , https://www.mdpi.com/2218-273X/14/2/159
21. Regulation of β-Adrenergic Receptors in the Heart: A Review on Emerging Therapeutic Strategies for Heart Failure – MDPI,  , https://www.mdpi.com/2073-4409/13/20/1674
22. Robert J. Lefkowitz – Nobel Lecture: A Brief History of … – Nobel Prize,  , https://www.nobelprize.org/uploads/2018/06/lefkowitz-lecture.pdf
23. Introduction of Robert J. Lefkowitz – PMC,  , https://pmc.ncbi.nlm.nih.gov/articles/PMC3195491/
24. Press release: The Nobel Prize in Chemistry 2012 – NobelPrize.org,  , https://www.nobelprize.org/prizes/chemistry/2012/press-release/
25. The Nobel Prize in Chemistry 2012 – Popular information – NobelPrize.org,  , https://www.nobelprize.org/prizes/chemistry/2012/popular-information/
26. Brian Kobilka – Wikipedia,  , https://en.wikipedia.org/wiki/Brian_Kobilka
27. Molecular cloning and expression of the cDNA for the hamster alpha 1-adrenergic receptor. | PNAS,  , https://www.pnas.org/doi/10.1073/pnas.85.19.7159
28. Molecular tinkering of G protein‐coupled receptors: an evolutionary success – EMBO Press,  , https://www.embopress.org/doi/10.1093/emboj/18.7.1723
29. Discovery of β2 Adrenergic Receptor Ligands Using Biosensor …,  , https://pubs.acs.org/doi/10.1021/ml400312j
30. Brian K. Kobilka – NAS – National Academy of Sciences,  , https://www.nasonline.org/directory-entry/brian-k-kobilka-jvdmgd/
31. Discovery of New GPCR biology – One Receptor Structure at a Time – PubMed Central,  , https://pmc.ncbi.nlm.nih.gov/articles/PMC2813843/
32. Alpha- and beta-adrenergic receptors: Ahlquist’s landmark hypothesis of a single mediator with two receptors. – Semantic Scholar,  , https://www.semanticscholar.org/paper/Alpha-and-beta-adrenergic-receptors%3A-Ahlquist%27s-of-Bylund/ffbdd73850451baa275fdd99adef4bcd8f9b567c
33. Beta 1 Receptors – StatPearls – NCBI Bookshelf,  , https://www.ncbi.nlm.nih.gov/books/NBK532904/
34. Dale’s principle – Wikipedia,  , https://en.wikipedia.org/wiki/Dale%27s_principle
35. Henry Hallett Dale – Wikipedia,  , https://en.wikipedia.org/wiki/Henry_Hallett_Dale